Treco Douglas A
- SEC CIK
- 0001688192
No open-market purchases or sales filed in the past year.
Current role at each company
- CRSP CRISPR Therapeutics AGDirectoras of Jun 9, 2026
- INZY Inozyme Pharma, Inc.CEO & Chairmanas of Jul 3, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Treco Douglas A as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CRSP CRISPR Therapeutics AG
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 8, 2025 (view filing) | Aug 6 | 2 days | Treco Douglas ADirector | PPurchase | +20.0K | $57.03 | +$1.14M | +1,000.0%22.0K after |
INZY Inozyme Pharma, Inc.
CEO & Chairman2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Treco Douglas ACEO & Chairman | SSale | −8.82K | $0.89 | −$7.85K | −17.7%41.0K after | |
| Apr 3, 2024 (view filing) | Apr 2 | 1 day | Treco Douglas ACEO | SSale | −7.52K | $6.94 | −$52.2K | −26.7%20.7K after |